Bladder test adopted by US healthcare alliance:
This article was originally published in Clinica
Executive Summary
US healthcare alliance Kaiser Permanente is to use Matritech's bladder cancer test, NMP22, for monitoring disease recurrence in its patients. The company says NMP22 is the only quantitative, non-invasive urine test for transitional cell carcinoma, which is responsible for 90% of bladder cancers. Worldwide more than two million people suffer from bladder cancer, which has a 70% recurrence rate. Kaiser Permanente has around 7.7 million members.